Exploratory Lapatinib (Positron Emission Tomography) PET Study in Subjects With Breast Cancer

Sponsor
GlaxoSmithKline
Study ID
NCT01290354
Phase
PHASE1
Status
Completed

Conditions

  • Cancer

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Lapatinib — DRUG
    Unlabelled, administered orally
  • [11C] lapatinib — DRUG
    Radiolabelled, administered intravenously

Study Details

The purpose of this study is to find out how much lapatinib can enter both normal brains and brains in which tumours secondary to breast cancer have developed.

Key Dates

Start date
Sep 12, 2011
Status verified
Nov 2017
Primary completion
Mar 18, 2013
Completion
Mar 18, 2013

Study Design

Enrollment
10 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Experimental: lapatinib
    unlabelled, administered orally

Primary Outcome Measure

Brain penetration of [11C]lapatinib [ Time Frame: 8 days ]

Related Studies